Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2016 ASCO Annual Meeting /
Consolidative therapy extends PFS for NSCLC patients

3rd - 7th Jun 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.16
Views: 1555
Rating:

Prof Daniel Richard Gomez - University of Texas MD Anderson Cancer Center, Houston, USA

Dr Gomez met with ecancertv at ASCO 2016 to discuss a phase II randomised study in which local consolidative therapy (LCT) was offered to patients with oligometastic non-small cell lung cancer (NSCLC).

Dr Gomez reports that, based on the DSMC recommendation, the study was closed early due to the significant efficacy benefit observed in the study arm.

The median PFS time in the LCT arm reached 14.4 months (95% CI 5.2 months-NR), compared to 3.9 months (95% CI 2.2-6.6 months) in the no-LCT arm (HR = 0.36, p = 0.013).

With these results, he is looking towards data maturation from overall survival times, and patient surveillance continues.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation